Management of hydroxyurea resistant or intolerant polycythemia vera
Journal Title
Leukemia & Lymphoma
Publication Type
e409
Abstract
Polycythemia vera is a Philadelphia negative myeloproliferative neoplasm characterized by erythrocytosis in which the major cause of morbidity and mortality is thrombosis. Aspirin and hematocrit reduction by venesection or cytoreductive therapy are at the cornerstone of management. First line cytoreductive therapy in high-risk patients is hydroxyurea; however, its use is associated with toxicities and resistance in a significant proportion of patients. In a disease with a long overall survival with appropriate treatment, it is imperative that other treatment options do not accelerate the risk of progression to acute leukemia. The following review will appraise the evidence of interferon, ruxolitinib, and other agents in management of hydroxyurea resistant or intolerant polycythemia vera.
Publisher
Taylor & Francis
Keywords
PEGylated interferon alpha; Polycythemia vera; hydroxyurea resistance/intolerance; ruxolitinib
Research Division(s)
Population Health And Immunity
PubMed ID
33949918
Open Access at Publisher's Site
https://doi.org/10.1080/10428194.2021.1901092
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2021-05-11 04:12:13
Last Modified: 2021-05-17 11:20:07
An error has occurred. This application may no longer respond until reloaded. Reload 🗙